Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-04T17:57:16.545Z Has data issue: false hasContentIssue false

Treatment with recombinant human tumour necrosis factor-α reduces parasitaemia and prevents Plasmodium berghei K173-induced experimental cerebral malaria in mice

Published online by Cambridge University Press:  01 January 1999

N. S. POSTMA
Affiliation:
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands
C. C. HERMSEN
Affiliation:
Department of Medical Microbiology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
D. J. A. CROMMELIN
Affiliation:
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands
J. ZUIDEMA
Affiliation:
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands
W. M. C. ELING
Affiliation:
Department of Medical Microbiology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands

Abstract

The present study shows that treatment with recombinant human tumour necrosis factor-α (rhTNF-α) can suppress parasitaemia and prevents development of experimental cerebral malaria (ECM) in Plasmodium berghei K173-infected mice. Mice received rhTNF-α treatment either by subcutaneous injection of free or liposome-encapsulated rhTNF-α or sustained intraperitoneal administration of rhTNF-α given via mini-osmotic pumps. Low-dose treatment with a subcutaneous bolus injection of rhTNF-α protected against ECM when treatment was started on day 5 or 6 after infection. The same protective efficacy was obtained either by subcutaneous injection of liposome-encapsulated rhTNF-α or by sustained release from osmotic pumps, but in the latter case a 10-fold lower daily dose of rhTNF-α was sufficient. Treatment with rhTNF-α substantially suppressed parasitaemia in ECM-protected mice, but not in mice developing ECM. Thus, the rhTNF-α mediated suppression of parasitaemia is directly or indirectly involved in protection against ECM. Sustained delivery of rhTNF-α through osmotic pumps, but not by subcutaneous injection of liposome-encapsulated rhTNF-α, resulted in increased concentrations of soluble mouse TNF receptor R75 (sTNFR75) in plasma at day 9 after infection when non-treated mice die of ECM. Thus, protection against ECM is not directly correlated with the sTNFR75 concentrations at day 9 after infection.

Type
Research Article
Copyright
1999 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)